Table 1.
Patient characteristics of chordoma cohorts. This table contains an overview of each cohort separately as well as both cohorts combined
| Variable | First | Second | Combined | |||
| Total patients, n | 32 | 53 | 85 | |||
| Gender, n (%) | ||||||
| Female | 15 | (46.9) | 21 | (39.6) | 36 | (42.4) |
| Male | 17 | (53.1) | 32 | (60.4) | 49 | (57.6) |
| Age (years), median (range) | 59 | (1–80) | 60 | (22–80) | 60 | (1–80) |
| Follow-up (months), median (range) | 66 | (0–418) | 41 | (0–182) | 50 | (0–418) |
| Anatomical location, n (%)* | ||||||
| Skull base (Clivus) | 8 | (25.0) | 17 | (32.1) | 25 | (29.4) |
|
Mobile spine (craniocervical, cervical, thoracic, lumbar) |
7 (0, 1, 4, 2) | (21.9) | 15 (3, 10, 1, 1) | (28.3) | 22 | (25.9) |
| Sacrococcygeal | 17 | (53.1) | 20 | (37.7) | 27 | (31.8) |
| Extra-axial (Costa) | – | – | 1 | (1.9) | 1 | (1.2) |
| Max tumor size (cm), median (IQR)† | 7 | (4.5) | 6 | (6.1) | 6.1 | (5.6) |
| Skull base (Clivus) | 2.8 | (0.88) | 4.3 | (1.5) | 4 | (2.5) |
|
Mobile spine (craniocervical, cervical, thoracic, lumbar) |
5.5 | (3.4) | 4.9 | (1.4) | 5 | (1.7) |
| Sacrococcygeal | 8 | 4 | 10.5 | (3.6) | 9 | (3.9) |
| Extra-axial (Costa) | – | – | 10 | – | 10 | – |
| Treatment, n (%) | ||||||
| Radiotherapy alone | – | – | 11 | (20.8) | 11 | (12.9) |
| Surgery alone | 21 | (65.6) | 19 | (35.8) | 40 | (47.1) |
| Surgery and radiotherapy | 11 | (34.4) | 23 | (43.4) | 34 | 40 |
| Other radiotherapy regimens, n (%) | ||||||
| Monotherapy, conventional | – | – | 1 | (1.9) | 1 | (1.2) |
| Monotherapy, proton beam | – | – | 9 | 17 | 9 | (10.6) |
| Monotherapy, carbon ion | – | – | 1 | (1.9) | 1 | (1.2) |
| Sandwich, proton beam | – | – | 2 | (3.8) | 2 | (2.4) |
| Preoperative radiotherapy, n (%)‡ | ||||||
| Conventional | 4 | (12.5) | 2 | (3.8) | 6 | (7.1) |
| Proton beam | 2 | (6.3) | 1 | (1.9) | 3 | (3.5) |
| Postoperative radiotherapy, n (%)‡ | ||||||
| Conventional | 5 | (15.6) | 7 | (13.2) | 12 | (14.1) |
| Proton beam | – | – | 11 | (20.8) | 11 | (12.9) |
| Patients with recurrent disease, n (%)§ | ||||||
| Local recurrence | 16 | (50) | 29 | (54.7) | 45 | (52.9) |
| Metastasis | 6 | (18.8) | 14 | (26.4) | 20 | (23.5) |
*Anatomical location of the primary tumors.
†Size was not available for 8 and 11 primary tumors in the initial and the additional cohort, respectively (4 skull base and 2 mobile spine; 2 skull base, 2 mobile spine and 7 sacrococcygeal).
‡Treatments regarding primary tumors.
§Patients who experienced recurrent disease during follow-up. With the exception of three patients in the additional cohort, metastatic disease followed local recurrence.